ADPKD with Markedly Enlarged Polycystic Liver Disease and Severe Volume-Related Symptoms

In autosomal dominant polycystic kidney disease (ADPKD), hepatic cyst burden can become the dominant source of morbidity. When polycystic liver disease results in marked organ enlargement and severe volume-related symptoms, a specific evidence-based intervention is recommended.

Clinical scenario: ADPKD in a patient with markedly enlarged polycystic liver and severe volume-related symptoms — a sub-population for whom targeted pharmacological therapy is guideline-supported (recommendation grade 1B).

Treatment approach: Current evidence supports long-acting somatostatin analogues as the recommended pharmacological intervention in this setting. The complete regimen — specific agent selection, dosing, and monitoring criteria — is detailed in the full protocol.

Treatment goal: Reduction in symptom burden and/or volume of the polycystic liver, with response evaluated after 6–12 months.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.kint.2024.07.010

We recommend prescribing long-acting somatostatin analogues in people with ADPKD and markedly enlarged polycystic livers with severe volume-related symptoms (1B).

When long-acting somatostatin analogues are prescribed, the effect on symptom burden and/or volume of polycystic livers and kidneys should be evaluated after 6–12 months. If beneficial effects of therapy are not observed, somatostatin analogues should be discontinued.

View source ↗